Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities with $45 Million Equity Investment from NewVale Capital and Telegraph Hill Partners
Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45 million financing to support its new drug product fill / finish expansion. This expansion in Carlsbad, CA, underway since early 2023, includes a new dedicated facility with a state-of-the-art isolator-based filling line that more than quadruples Argonaut’s existing drug product fill / finish capacity and augments existing vial filling capabilities with the ability to pre-fill syringes and cartridges for clinical and commercial supply. Argonaut expects to have fully validated the facility and all equipment in 2025.
The financing was led by NewVale Capital, a growth equity fund focused on innovative pharmaceutical and life science services businesses, with participation from existing majority investor Telegraph Hill Partners, and other current investors.
Wayne Woodard, founder and CEO of Argonaut, commented: “Argonaut is uniquely positioned to address the manufacturing challenges that biopharma innovators face related to sterile fill / finish of complex and high-value drug products. We remain laser focused on leveraging our experienced team’s commitment to flexibility and client satisfaction while prioritizing quality and compliance. The recent commitment from NewVale Capital and the continued support of Telegraph Hill Partners paves a straight path to capacity expansion and fulfillment of our mission to become the world’s best Drug Product Manufacturing solutions provider for our clients.”
“We are thrilled to partner with Telegraph Hill to support the experienced team at Argonaut, building upon their strong foundation,” said Todd Holmes, Managing Partner of NewVale Capital. “For years, small- and medium-sized biopharma companies have struggled to find reliable, high-quality fill / finish capabilities from providers that prioritize their molecules. With this capital infusion, we can further enable Argonaut’s mission that no innovator, regardless of size, should be waitlisted behind larger pharma or be forced to compromise on quality when trying to bring critical therapies to patients.”
Argonaut’s FDA-registered facilities are compliant with 21 CFR parts 210, 211, and 820 and offer highly flexible and scalable solutions for a broad range of biopharmaceuticals including monoclonal antibodies, proteins, peptides, oligonucleotides, and small molecules. Additionally, Argonaut maintains an ISO 13485:2016 certification to produce drug-device combination products. Argonaut’s quality systems have been successfully audited by many biopharma customers and global regulatory agencies including the FDA and PMDA.
“The recent consolidation in the aseptic fill / finish market has highlighted the need for additional capacity to ensure patients have uninterrupted access to critical life-saving and life-extending therapies,” stated Chris Duffy, SVP/GM of Biopharma Services at Argonaut. “Our deep expertise in fill / finish, coupled with our planned expansion will help address this need for our clients and we remain ready to take on new projects.”
RBC Capital Markets LLC served as exclusive placement agent to Argonaut.
About Argonaut Manufacturing Services
Argonaut Manufacturing Services is an FDA-registered cGMP contract development and manufacturing organization (CDMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill / finish capabilities feature state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecules, and vaccines. Diagnostic manufacturing capabilities include proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the biopharma, life science, and molecular diagnostics industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. For more information, visit: www.argonautms.com.
About Telegraph Hill Partners
Founded in 2001, Telegraph Hill Partners invests in life science, medical device, and healthcare technology companies. For more information, visit: www.telegraphhillpartners.com.
About NewVale Capital
Founded in 2022, NewVale Capital is a growth equity firm that focuses on supporting the next generation of life science services companies. The firm invests in proven, revenue-generating services businesses across the life science ecosystem that are helping to bring medicines to patients. For more information, visit: www.newvalecapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305644445/en/
Contact information
Brainspores
Marianne Woodard
Marianne.woodard@brainspores.com
408-313-8583
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Fintech Company iCard Achieves Secure Customer Verification in Under 60 Seconds with Regula’s Solutions7.5.2025 09:00:00 EEST | Press release
iCard, a leading European e-money institution, has successfully upgraded its customer checks with Regula’s advanced biometric and document verification technologies. By integrating Regula Face SDK and Regula Document Reader SDK with its KYC (Know Your Customer) and risk assessment systems, iCard has moved to speedy, automated verification with improved fraud detection, and enhanced the overall experience for customers in 30+ countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506829598/en/ iCard streamlines onboarding and boosts fraud prevention by integrating Regula’s document and biometric verification technologies (Graphic: Regula) As a licensed fintech organization, iCard must comply with strict European KYC regulations while maintaining a robust risk assessment system alongside low-effort customer experience. Prior to implementing Regula’s solutions, manual verification processes led to inefficiencies, longer w
IFF Reports First Quarter 2025 Results6.5.2025 23:35:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2025. Management Commentary “IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business,” said IFF CEO Erik Fyrwald. “Our growth, combined with ongoing productivity initiatives, contributed to a meaningful increase in profitability. We also successfully completed the divestiture of our Pharma Solutions business two months ahead of schedule, a key milestone that supports the achievement of our targeted debt leverage ratio." “As we navigate the heightened macroeconomic uncertainty in today’s environment, we remain focused on what we can control - collaborating with our customers to drive growth, investing in innovation and delivering increased productivity. We are maintaining our full-year financial guidance ranges but recognize that the uncertain environment has potential for more challenges, yet we remain confident in our long-term strategy
Lattice to Showcase Advanced Edge AI Solutions at New-Tech 2025 Exhibition6.5.2025 23:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it will showcase its latest FPGA technology at the New-Tech 2025 Exhibition. Lattice technology demos will be featured in the Telsys Ltd. booth, showcasing industry-leading low power, small form factor FPGAs and application-specific solutions enabling advanced embedded vision, artificial intelligence, and sensor fusion capabilities. Additionally, Lattice will deliver a technical presentation titled “Power-Efficient Robotics and Automation Fueled by Lattice FPGA Technology” about how advanced, power-optimized FPGAs can dramatically reduce power consumption for next-generation automation and robotics solutions for Industrial applications. Who: Lattice Semiconductor What / When: May 20 – 21: Lattice demo showcase (Telsys Ltd. Booth #67-68) May 21, 10:20 a.m.: “Power-Efficient Robotics and Automation Fueled by Lattice Semiconductor FPGA Technology” technical presentation Where: New-Tech 2025 Exhib
Rockstar Games Releases Trailer 2 for Grand Theft Auto VI6.5.2025 19:37:00 EEST | Press release
Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is proud to announce the release of Trailer 2 for Grand Theft Auto VI, alongside a closer look at the biggest, most immersive evolution of the series yet: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506495901/en/ Set to launch on May 26, 2026, on PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems, Grand Theft Auto VI will soon be available for wishlisting on both the PlayStation and Microsoft Stores. Vice City, USA. Jason and Lucia have always known the deck is stacked against them. But when an easy score goes wrong, they find themselves on the darkest side of the sunniest place in America, in the middle of a criminal conspiracy stretching across the state of Leonida — forced to rely on each other more than ever if they want to make it out alive. Further details can be found at www.r
Monroe Capital, SMBC and MA Financial Launch US$1.7 Billion Middle Market Lending Joint Venture6.5.2025 17:07:00 EEST | Press release
Monroe Capital, Sumitomo Mitsui Banking Corporation (SMBC) and MA Asset Management (part of MA Financial Group, ASX: MAF) today announced the formation of a new joint venture (“JV”), which will invest up to US$1.7 billion in senior secured loans to U.S. middle market borrowers. The JV harnesses the complementary capabilities of the three partnering institutions to establish a differentiated platform focused on the attractive middle market subset of private credit. The JV expects to benefit from broad access to high-quality, proprietary deal flow of first-lien senior-secured loans to established middle market companies, leveraging the loan origination capabilities of Monroe Capital’s direct lending infrastructure, SMBC’s established private credit and sponsor finance platform and MA Financial’s expertise in specialty credit and co-lending. The JV’s investable capital will be provided by Monroe Capital, SMBC and MA Financial (via its managed funds). Monroe Capital is one of the largest l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom